Iron overload in myelodysplastic syndromes (Q37093678)

18 August 2017

1 reference

title

Iron overload in myelodysplastic syndromes. (English)

1 reference

18 August 2017

1 reference

Sameer Mahesh

1

1 reference

18 August 2017

Yelena Ginzburg

series ordinal

2

1 reference

18 August 2017

Amit Verma

series ordinal

3

1 reference

18 August 2017

publication date

1 March 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

49

1 reference

18 August 2017

issue

3

1 reference

18 August 2017

page(s)

427-438

1 reference

https://api.crossref.org/works/10.1080%2F10428190701843221

18 August 2017

1 reference

The myelodysplastic syndromes: diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701843221

Survival analysis and AML development in patients with de novo myelodysplastic syndromes: comparison of six different prognostic scoring systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701843221

Utility of the FAB classification for myelodysplastic syndromes: investigation of prognostic factors in 237 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701843221

World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701843221

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701843221

Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701843221

Hepcidin, a urinary antimicrobial peptide synthesized in the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701843221

Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701843221

Severe iron deficiency anemia in transgenic mice expressing liver hepcidin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701843221

The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701843221

Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701843221

Iron release from macrophages after erythrophagocytosis is up-regulated by ferroportin 1 overexpression and down-regulated by hepcidin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701843221

Regulation of iron metabolism by hepcidin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701843221

Hepcidin in iron overload disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701843221

Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701843221

LPI-labile plasma iron in iron overload

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701843221

The importance of non-transferrin bound iron in disorders of iron metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701843221

Labile plasma iron in iron overload: redox activity and susceptibility to chelation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701843221

Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded beta-thalassemia/HbE patients treated with an oral chelator

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701843221

Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701843221

Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701843221

Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701843221

Noninvasive methods for quantitative assessment of transfusional iron overload in sickle cell disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701843221

Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701843221

Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701843221

Zygomycetes in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701843221

Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701843221

Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701843221

Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701843221

A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701843221

Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701843221

Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701843221

New advances in iron chelation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701843221

A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701843221

Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701843221

Myelodysplastic syndromes: iron overload consequences and current chelating therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701843221

Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701843221

Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701843221

10.1080/10428190701843221

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference